Hovione
Hovione, established in 2015, is a Portugal-based pharmaceutical company specializing in the manufacturing of drug substances for off-patent and new drugs. It focuses on complex drug testing, molecule screening, and particle engineering to accelerate and enhance drug development, particularly in dermatology, ophthalmology, and respiratory fields. Hovione partners with pharmaceutical customers to complete clinical development, regulatory approval, and commercialization, aiming to make treatments faster and more affordable.
SolasCure
Series A in 2021
SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on developing innovative solutions for patients with chronic wounds. Founded in 2017, the company is advancing its product Aurase, a hydrogel designed to facilitate wound debridement by removing dead, damaged, or infected tissue to enhance healing. Aurase incorporates a recombinant enzyme derived from maggots, leveraging biomimicry and evidence-based medicine to improve wound care outcomes. SolasCure aims to provide effective wound bed preparation across various healthcare settings, ultimately accelerating the healing process for individuals suffering from chronic wounds.
SolasCure
Seed Round in 2018
SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on developing innovative solutions for patients with chronic wounds. Founded in 2017, the company is advancing its product Aurase, a hydrogel designed to facilitate wound debridement by removing dead, damaged, or infected tissue to enhance healing. Aurase incorporates a recombinant enzyme derived from maggots, leveraging biomimicry and evidence-based medicine to improve wound care outcomes. SolasCure aims to provide effective wound bed preparation across various healthcare settings, ultimately accelerating the healing process for individuals suffering from chronic wounds.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.